Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig M Comisar

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|November 4, 2024
Population pharmacokinetic modeling of zavegepant, a calcitonin gene-related peptide receptor antagonist, in healthy adults and patients with migraineCraig M Comisar, Jose Francis, Jim H Hughes, et al.
Clinical and Translational Science|October 17, 2025
Exposure Matching Using Population Pharmacokinetic Modeling and Simulation to Support Rimegepant Dose Selection for Pediatric Patients With MigraineCraig M Comisar, Jim H Hughes, Gary Mo, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 4, 2025
Population Pharmacokinetic Modeling of the Oral Calcitonin Gene-Related Peptide Receptor Antagonist Rimegepant in AdultsCraig M Comisar, Jim H Hughes, Jose Francis, et al.
Headache|October 24, 2025
A phase 1, multicenter, open-label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged ≥6 to <12 years) with a history of migraineChay Ngee Lim, Gary Mo, Rajinder Bhardwaj, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
CPT: Pharmacometrics & Systems Pharmacology|November 4, 2024
Population pharmacokinetic modeling of zavegepant, a calcitonin gene-related peptide receptor antagonist, in healthy adults and patients with migraineCraig M Comisar, Jose Francis, Jim H Hughes, et al.
Clinical and Translational Science|October 17, 2025
Exposure Matching Using Population Pharmacokinetic Modeling and Simulation to Support Rimegepant Dose Selection for Pediatric Patients With MigraineCraig M Comisar, Jim H Hughes, Gary Mo, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 4, 2025
Population Pharmacokinetic Modeling of the Oral Calcitonin Gene-Related Peptide Receptor Antagonist Rimegepant in AdultsCraig M Comisar, Jim H Hughes, Jose Francis, et al.
Headache|October 24, 2025
A phase 1, multicenter, open-label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged ≥6 to <12 years) with a history of migraineChay Ngee Lim, Gary Mo, Rajinder Bhardwaj, et al.
Pageof 1